vasodilating drugs, except for ACE inhibitors, were excluded on the infusion days. None of the patients had oral warfarin due to PH. Iloprost treatment was given during the cold season of the year (October-March).
The systolic pulmonary artery pressure (PAPsyst) was determined by Doppler cardiography as previously described [8] , and evaluated by the same cardiologist before and after 24 weeks. PH was defined as > 32 mmHg. A change in PAPsyst > 5 mmHg was regarded as significant.
PAPsyst decreased in three patients by 9, 11 and 13 mmHg, whereas it was stable (± 5 mmHg) in the remaining five patients (Fig. 1) . The poorest response was found among smokers (Table I) . Five patients noticed improvement of Raynaud's phenomenon, i.e. less severe and less frequent vasospastic attacks, and 3/5 patients reported peripheral wound healing. All patients reported considerable subjective improvement in their well-being. Seven patients experienced headache and five nausea and/or diarrhoea during the infusions.
Previously described long-term continuous prostacyclin infusion therapy is both time consuming and expensive, but gains longer lifetime in patients awaiting lung transplantation [9] . Because of the reported long-lasting effect of intermittent iloprost infusion on peripheral circulation, we examined the effect of this regime on PH in SSc. Since at the start of the study there was no previous experience of the treatment of PH in SSc with intermittent iloprost, our treatment approach was based on the already described regimen in patients with Raynaud's phenomenon secondary to SSc [5] .
A beneficial effect of intermittent iloprost infusion on PH in SSc was recently reported by Bartram et al. [10] . The greater reduction of the pulmonary pressure among their patients may be explained by a shorter disease duration, a higher percentage of patients with ISSc without pulmonary fibrosis (80% compared to 38% in our study) or by the different treatment regime. It remains to be shown whether another treatment Resolving Familial Mediterranean Fever Attacks with Interferon Alpha SIR-Attacks of familial Mediterranean fever (FMF) can be decreased by colchicine and this drug also possibly prevents amyloidosis, the most serious complication of the disease. Ten to 20 per cent of the patients continue to have painful attacks despite colchicine therapy, however. We recently treated a patient with FMF and chronic hepatitis whose uncontrolled attacks with colchicine therapy completely resolved after interferon a treatment.
A 40-yr-old man was referred to our gastroenterology department because of persistently elevated liver enzymes for the last 6 months. He had had typical attacks of FMF with abdominal pain and fever since the age of 16 yr. The disease was also present in his grandfather, one sister and a nephew. These relatives were symptom free with colchicine therapy and had no liver function abnormalities. Our patient began treatment with colchicine in 1976 and initially he used the drug intermittently. Because his attacks continued to occur twice a week, he was advised to take 1.5 mg/day of colchicine regularly. For the previous 6 months, he had been taking 2 mg of colchicine per day without any decrease in the number or severity of attacks. On presentation to us, his ALT was 132 IU/1, AST 94IU/1, alkaline phosphatase 90 IU/1, GGT 83 IU/1, total protein 6.6 g/dl, albumin 4.5 g/dl and total bilurubin l.Omg/dl. His upper abdominal ultrasonography was normal. HBsAg and HBeAg were positive, and HBV DNA was 16 pg/ml. A liver biopsy was performed and chronic hepatitis with moderate activity was found.
Interferon a (Intron A, Schering Plough) was started at 10 million units three times a week. Immediately after the first dose, his FMF attacks disappeared completely. He is at the sixth month of treatment and did not have an attack until now. His liver enzymes began to fall during the first month of treatment and at the sixth month his ALT was within normal limits. The patient has stopped taking colchicine for the last 4 months on his own initiative, against our recommendations.
The pathogenesis of FMF attacks is poorly understood. Increased levels of tumour necrosis factor (TNF) a and decreased inhibitors of complement fragment C5a and interleukin-8 may individually or concurrently cause the inflammation [1, 2] . Interferon a has some anti-inflammatory properties but, interestingly, although the actions of interferon a on TNF are not as evident as those of interferon gamma, it was shown to increase TNF and TNF receptors in recent studies [3] . Thus, the mechanism of
